Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2011 1
2012 1
2013 1
2014 2
2015 3
2016 2
2017 5
2018 1
2019 4
2020 3
2021 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Oxaliplatin-Induced Evans Syndrome: A Possible Dual Mechanism.
Rousseau C, Nguyen TN, Rebibou JM, Bastie JN, Audia S, Darut-Jouve A, Legendre M. Rousseau C, et al. Among authors: darut jouve a. Clin Colorectal Cancer. 2020 Mar;19(1):57-60. doi: 10.1016/j.clcc.2019.11.001. Epub 2019 Nov 26. Clin Colorectal Cancer. 2020. PMID: 31883972 No abstract available.
Panitumumab in combination with chemoradiotherapy for the treatment of locally-advanced anal canal carcinoma: Results of the FFCD 0904 phase II trial.
Vendrely V, Ronchin P, Minsat M, Le Malicot K, Lemanski C, Mirabel X, Etienne PL, Lièvre A, Darut-Jouve A, de la Fouchardière C, Giraud N, Breysacher G, Argo-Leignel D, Thimonnier E, Magné N, Abdelghani MB, Lepage C, Aparicio T; for FFCD investigators/Collaborators. Vendrely V, et al. Among authors: darut jouve a. Radiother Oncol. 2023 Sep;186:109742. doi: 10.1016/j.radonc.2023.109742. Epub 2023 Jun 12. Radiother Oncol. 2023. PMID: 37315583 Free article. Clinical Trial.
FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial.
Tougeron D, Dahan L, Evesque L, Le Malicot K, El Hajbi F, Aparicio T, Bouché O, Bonichon Lamichhane N, Chibaudel B, Angelergues A, Bodere A, Phelip JM, Mabro M, Kaluzinski L, Petorin C, Breysacher G, Rinaldi Y, Zaanan A, Smith D, Gouttebel MC, Perret C, Etchepare N, Emile JF, Sanfourche I, Di Fiore F, Lepage C, Artru P, Louvet C; PRODIGE 59-FFCD 1707-DURIGAST Investigators/Collaborators. Tougeron D, et al. JAMA Oncol. 2024 Apr 4. doi: 10.1001/jamaoncol.2024.0207. Online ahead of print. JAMA Oncol. 2024. PMID: 38573643
Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort.
Pivot X, Romieu G, Fumoleau P, Rios M, Bonnefoi H, Bachelot T, Soulié P, Jouannaud C, Bourgeois H, Petit T, Tennevet I, Assouline D, Mathieu MC, Jacquin JP, Lavau-Denes S, Darut-Jouve A, Ferrero JM, Tarpin C, Lévy C, Delecroix V, Trillet-Lenoir V, Cojocarasu O, Meunier J, Pierga JY, Agostini C, Kerbrat P, Faure-Mercier C, Blanché H, Sahbatou M, Boland A, Bacq D, Besse C, Calvo F, Renaud A, Deleuze JF, Pauporté I, Thomas G, Cox DG. Pivot X, et al. Among authors: darut jouve a. NPJ Breast Cancer. 2017 Feb 23;3:4. doi: 10.1038/s41523-017-0005-y. eCollection 2017. NPJ Breast Cancer. 2017. PMID: 28649644 Free PMC article.
MRI-Based Radiomics Input for Prediction of 2-Year Disease Recurrence in Anal Squamous Cell Carcinoma.
Giraud N, Saut O, Aparicio T, Ronchin P, Bazire LA, Barbier E, Lemanski C, Mirabel X, Etienne PL, Lièvre A, Cacheux W, Darut-Jouve A, De la Fouchardière C, Hocquelet A, Trillaud H, Charleux T, Breysacher G, Argo-Leignel D, Tessier A, Magné N, Ben Abdelghani M, Lepage C, Vendrely V. Giraud N, et al. Among authors: darut jouve a. Cancers (Basel). 2021 Jan 7;13(2):193. doi: 10.3390/cancers13020193. Cancers (Basel). 2021. PMID: 33430396 Free PMC article.
Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes.
Curtit E, Pivot X, Henriques J, Paget-Bailly S, Fumoleau P, Rios M, Bonnefoi H, Bachelot T, Soulié P, Jouannaud C, Bourgeois H, Petit T, Tennevet I, Assouline D, Mathieu MC, Jacquin JP, Lavau-Denes S, Darut-Jouve A, Ferrero JM, Tarpin C, Lévy C, Delecroix V, Trillet-Lenoir V, Cojocarasu O, Meunier J, Pierga JY, Kerbrat P, Faure-Mercier C, Blanché H, Sahbatou M, Boland A, Bacq D, Besse C, Thomas G, Deleuze JF, Pauporté I, Romieu G, Cox DG. Curtit E, et al. Among authors: darut jouve a. Breast Cancer Res. 2017 Aug 22;19(1):98. doi: 10.1186/s13058-017-0888-4. Breast Cancer Res. 2017. PMID: 28830573 Free PMC article.
24 results